Evidence map›Paper›PMID 36121499›Full record

ArticleEuropean journal of clinical pharmacology2022

The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study.

Mohamed Nabil Elshafei, Yahia Imam, Arwa Ebrahim Alsaud, Prem Chandra, Aijaz Parray, Mohamed S Abdelmoneim, Khaldun Obeidat, Razan Saeid, Mohammad Ali, Raheem Ayadathil and 5 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04330872 (An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04330872 phase4completednot on this map

An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.

TypeinterventionalSponsorHamad Medical CorporationRan2019 to 2020Enrolled42ConditionsStroke, IschemicArmsEnteric Coated Aspirin Tablet, Plain Aspirin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in immunology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Mohamed Nabil Elshafei *Clinical Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, P.O. 3050, Doha, Qatar. mohnabil2010@yahoo.com.ORCID http://orcid.org/0000-0002-3229-6825
Yahia Imam *Neurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Arwa Ebrahim AlsaudInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Prem Chandra *Biostatstics Section, Medical Research Center, Hamad Medical Corporation, Doha, Qatar.
Aijaz Parray *The Neuroscience Institute, Academic Health Systems, Hamad Medical Corporation, Doha, Qatar.
Mohamed S AbdelmoneimNeurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Khaldun ObeidatInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Razan SaeidInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohammad AliInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Raheem AyadathilThe Neuroscience Institute, Academic Health Systems, Hamad Medical Corporation, Doha, Qatar.
Mouhand F H MohamedInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Ibtihal M AbdallahClinical Pharmacy Department, Hamad General Hospital, Hamad Medical Corporation, P.O. 3050, Doha, Qatar.
Shaban MohammedDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
Naveed AkhtarNeurology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohammed Ibn-Masoud DanjumaInternal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad General Hospital · QAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeUncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke.

methodsA prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020).

resultsOf 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%; P = 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27; P = 0.047). No incidence of GIT bleeding observed throughout the study.

conclusionA significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.

Indexed as

AspirinIschemic StrokeGastrointestinal HemorrhageGlycated HemoglobinHumansPlatelet Aggregation InhibitorsProspective StudiesThromboxane B2AspirinGlycated HemoglobinPlatelet Aggregation InhibitorsThromboxane B2Aspirin responseEnteric-coated aspirinPlain aspirinStrokeThromboxane B2

Identifiers

PMID36121499
PMCPMC9546947
OpenAlexW4296323733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.